+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

SARS coronavirus anti-infectives



SARS coronavirus anti-infectives



Recent Patents on Anti-Infective Drug Discovery 1(3): 297-308



Severe acute respiratory syndrome (SARS) emerged in late 2002 and was controlled in July 2003 by public health measures. Its causative agent, SARS coronavirus (SARS-CoV) jumped from an animal reservoir to humans and has the potential to re-emerge. Following the sequencing of the genetic code and the deciphering of some of the functions of its proteins, including the cellular receptors and host proteins that participate in the life cycle of the virus, promising lead drugs and new uses of old drugs have been discovered. Patent applications for cathepsin L inhibitors have taken new relevance because of the role of cathepsin L in the entry of SARS-CoV into host cells. Likewise, patent applications for SARS-CoV protease inhibitors and interferon and mismatched dsRNA also need to be watched for potential application in treatment and prevention of SARS-CoV. Here, we review the recent advances and inventions that target SARS-CoV infection in humans.

Please choose payment method:






(PDF emailed within 1 workday: $29.90)

Accession: 055630467

Download citation: RISBibTeXText

PMID: 18221155


Related references

Sars Coronavirus Anti-Infectives. Recent Patents on Anti-Infective Drug Discovery 1(3): 297-308, 2006

Anti-SARS virus antibody responses against human SARS-associated coronavirus and animal SARS-associated coronavirus-like virus. Chinese Medical Journal 117(11): 1723-1725, 2004

Differential sensitivities of severe acute respiratory syndrome (SARS) coronavirus spike polypeptide enzyme-linked immunosorbent assay (ELISA) and SARS coronavirus nucleocapsid protein ELISA for serodiagnosis of SARS coronavirus pneumonia. Journal of Clinical Microbiology 43(7): 3054-3058, 2005

Detection of the anti-SARS-coronavirus specific antibody levels in 156 SARS patients. Zhongguo Shi Yan Xue Ye Xue Za Zhi 11(5): 441-443, 2003

Potential targets for anti-SARS drugs in the structural proteins from SARS related coronavirus. Peptides 25(6): 901-908, 2004

Structure and dynamics of SARS coronavirus proteinase: The primary key to the designing and screening for anti-SARS drugs. ScienceAsia 29(2): 181-188, 2003

Derivation of a novel SARS-coronavirus replicon cell line and its application for anti-SARS drug screening. Virology 360(1): 150-158, 2007

Dynamics of anti-SARS coronavirus IgG antibody in SARS patients. Applied Immunohistochemistry & Molecular Morphology 11(4): 302, 2003

Exploring the binding mechanism of the main proteinase in SARS-associated coronavirus and its implication to anti-SARS drug design. Bioorganic and Medicinal Chemistry 12(9): 2219-2223, 2004

Characterization of trans- and cis-cleavage activity of the SARS coronavirus 3CLpro protease: basis for the in vitro screening of anti-SARS drugs. Febs Letters 574(1-3): 131-137, 2004

Alisporivir inhibits MERS- and SARS-coronavirus replication in cell culture, but not SARS-coronavirus infection in a mouse model. Virus Research 228: 7, 2017

Mutagenesis of the transmembrane domain of the SARS coronavirus spike glycoprotein: refinement of the requirements for SARS coronavirus cell entry. Virology Journal 6: 230, 2009

Evidence of the recombinant origin of a bat severe acute respiratory syndrome (SARS)-like coronavirus and its implications on the direct ancestor of SARS coronavirus. Journal of Virology 82(4): 1819-1826, 2008

Development of a quantitative assay for SARS coronavirus and correlation of GAPDH mRNA with SARS coronavirus in clinical specimens. Journal of Clinical Pathology 58(3): 276-280, 2005

Difference in receptor usage between severe acute respiratory syndrome (SARS) coronavirus and SARS-like coronavirus of bat origin. Journal of Virology 82(4): 1899-1907, 2008